Key Highlights
● Third-quarter sales were $25.4 billion, up 5.9% from a year earlier.
● GAAP net earnings were $210 million, down 95.9%, after a one-time special charge.
● Adjusted diluted EPS was $2.59, down 7.5% from $2.80.
● 2026 adjusted diluted EPS guidance is $11.05 to $11.15.
Johnson & Johnson (NYSE:JNJ) reported third-quarter 2026 results on 13 October 2026. Reported sales were $25.4 billion, up 5.9 per cent from $23.99 billion a year earlier; operational growth was 6.0 per cent. GAAP net earnings were only $210 million, down 95.9 per cent, and GAAP diluted earnings per share were $0.09, against $2.12. Adjusted net earnings were $6.34 billion, down 6.8 per cent, and adjusted diluted earnings per share were $2.59, down 7.5 per cent from $2.80. The company attributes the GAAP fall to a one-time special charge connected with a proposed resolution of ovarian talc litigation, together with the Firefly Bio acquisition and a collaboration with Sail Biomedicines. Free cash flow was about $15.1 billion, against $14.2 billion.
Segment and product performance
Innovative Medicine sales were $16.76 billion, up 7.7 per cent reported and 8.0 per cent on an adjusted operational basis. MedTech sales were $8.64 billion, up 2.5 per cent on both measures. US sales rose 9.1 per cent to $14.96 billion, while international sales rose 1.5 per cent reported to $10.44 billion. Growth drivers named by the company include Tremfya, Darzalex, Carvykti, Tecvayli, Rybrevant and Lazcluze, Erleada, Spravato and Caplyta, and in MedTech electrophysiology, Shockwave, contact lenses and trauma.
Headwinds included Stelara, which reduced growth by about 690 basis points, plus Simponi, Remicade, Opsumit and Imbruvica. The pattern is one of newer medicines offsetting loss of exclusivity, with slower MedTech growth. A September preview put consensus third-quarter sales at $25.29 billion, up 5.4 per cent, so reported sales were modestly higher than that expectation. Innovative Medicine supplied about two thirds of sales.
The talc charge and deals
The proposed talc resolution is the main non-operating item. The release says the third-quarter GAAP results include a one-time special charge but does not state the settlement amount, so the size of any payment cannot be derived from the document. The same line also covers the completed Firefly Bio acquisition and the Sail Biomedicines collaboration, and the release does not split the charge between them. Regulatory milestones in the period included US approval of Imaavy for warm autoimmune haemolytic anaemia, US market authorisation of the Ottava robotic surgical system, and priority review for Rybrevant Faspro in advanced head and neck cancer.
Updated 2026 guidance
Johnson & Johnson updated its 2026 guidance. Estimated reported sales are now $101.0 billion to $101.4 billion, midpoint $101.2 billion, from $100.8 billion to $101.4 billion in July. Adjusted operational sales growth is expected at 6.4 per cent to 6.8 per cent. Adjusted diluted earnings per share are guided at $11.05 to $11.15, midpoint $11.10, up $0.06 at the midpoint from $11.04, and the guidance assumes a euro rate of $1.15. Adjusted operational earnings per share are guided at $10.95 to $11.05, midpoint $11.00. Guidance is management's expectation.
Talc Litigation, Orthopaedics Separation and Volatile Quarterly Results
The company's cautionary statement lists currency and interest rates, patent challenges and expiries, clinical and regulatory uncertainty, manufacturing and supply problems, product safety and recalls, significant litigation including product liability, healthcare reform and pricing pressure, and execution of strategic plans. It also lists the ability to separate the Orthopaedics business and realise the expected benefits; a pre-results preview describes that separation as targeted for mid-2027. The release does not mention a dividend. Quarterly results may be volatile while litigation provisions are settled. The same preview says management targeted at least 50 basis points of operating margin improvement for 2026.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...